Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion official investor newsroom · Indexed industry source record · Source published: Wed Aug 05 2026 10:30:38 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:50 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program August 5, 2026 at 6:30 AM EDT PDF Version Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery REC-4881
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.